MERTK and non-small cell lung carcinoma: Dual inhibition strategies have also emerged, including UNC9435, the first TYRO3/MERTK dual inhibitor [27] and macrocyclic MERTK/AXL inhibitors with promising activity in non-small cell lung cancer [28].